Kyowa Kirin Co., Ltd. (OTCMKTS:KYKOF – Get Free Report) was up 14.6% during trading on Tuesday . The company traded as high as $18.00 and last traded at $18.00. Approximately 800 shares traded hands during trading, a decline of 78% from the average daily volume of 3,650 shares. The stock had previously closed at $15.71.
Analysts Set New Price Targets
Separately, The Goldman Sachs Group lowered shares of Kyowa Kirin to a “sell” rating in a research report on Tuesday, December 16th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.
Get Our Latest Report on KYKOF
Kyowa Kirin Stock Performance
Kyowa Kirin Company Profile
Kyowa Kirin Co, Ltd. is a global biopharmaceutical company headquartered in Tokyo, Japan, specializing in the research, development and commercialization of innovative therapies. Established through the merger of Kyowa Hakko Kogyo Co, Ltd. and Kirin Pharma Co, Ltd. in 2008, the company operates as part of the Kirin Group and pursues a mission of delivering cutting-edge medicines in areas of high unmet medical need. Its corporate structure supports integrated research and development, manufacturing and worldwide licensing activities.
The company’s therapeutic focus spans oncology, nephrology, immunology and central nervous system disorders.
See Also
- Five stocks we like better than Kyowa Kirin
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This makes me furious
Receive News & Ratings for Kyowa Kirin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyowa Kirin and related companies with MarketBeat.com's FREE daily email newsletter.
